Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Elin Lindhagen"'
Autor:
Elin Lindhagen, Rolf Larsson, Caroline Haglund, Lena Håkansson, Anna Åleskog, Martin Höglund, Stefan Jacobsson
Publikováno v:
Toxicology Letters. 194:102-107
One of the most common dose limiting adverse effects in cancer treatment is myelotoxicity. The aim of this study was to develop an in vitro method for measuring potential myelotoxic properties of a drug candidate in a high throughput setting. Human C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d833368bff17d0de3eab74b5571ca01e
https://doi.org/10.1016/j.toxlet.2010.02.006
https://doi.org/10.1016/j.toxlet.2010.02.006
Autor:
Richard Rosenquist, Anna Åleskog, Mats G. Gustafsson, Maria Norberg, Christer Sundström, Elin Lindhagen, Magnus Åberg, Gerard Tobin, Meena Kanduri, Laura Säisänen
Publikováno v:
European Journal of Haematology. 83:22-34
Chronic lymphocytic leukemia (CLL) is a heterogeneous malignancy displaying varying clinical outcome, where molecular markers today can divide patients into prognostic subgroups. Despite the introduction of new agents for treatment, remissions are us
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c800354e2a1723c81495ed2ac374de3
https://doi.org/10.1111/j.1600-0609.2009.01248.x
https://doi.org/10.1111/j.1600-0609.2009.01248.x
Publikováno v:
Toxicology in Vitro. 21:1174-1181
Several in vitro methods have been suggested to predict drug-induced haematotoxicity and species differences; the most commonly used being the clonogenic CFU-GM assay. The aim of the current study was to evaluate whether primary lymphocytes from peri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e015860ffca8e6eb7c0e27643f0026c
https://doi.org/10.1016/j.tiv.2007.03.009
https://doi.org/10.1016/j.tiv.2007.03.009
Autor:
Lorenzo M. Leoni, Peter Nygren, Linda Rickardson, Elin Lindhagen, Gary Elliott, Anna Åleskog, Rolf Larsson
Publikováno v:
Investigational New Drugs. 25:297-303
SDX-308 and SDX-309 are potent indole-pyran analogues of SDX-101 (R-etodolac) which has anti-tumour activity unrelated to cyclooxygenase-2 inhibition. Their cytotoxic activity was further studied herein using a well-characterized human tumour cell-li
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab7f22b8dea6219be3ffb739bc7cd3ae
https://doi.org/10.1007/s10637-007-9049-4
https://doi.org/10.1007/s10637-007-9049-4
Autor:
Rolf Larsson, Elin Lindhagen, Bengt Simonsson, Ulla Olsson-Strömberg, Mats Bengtsson, Gisela Barbany, Martin Höglund, Anna Åleskog, Anneli Björnberg
Publikováno v:
Anti-Cancer Drugs. 17:631-639
The aims of this study were to evaluate the feasibility of using the non-clonogenic fluorometric microculture cytotoxicity assay in drug sensitivity testing of tumor cells from patients with chronic myeloid leukemia. In nine samples (six chronic phas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b38a67722cfde5214229b22b0c029a97
https://doi.org/10.1097/01.cad.0000217423.59831.db
https://doi.org/10.1097/01.cad.0000217423.59831.db
Autor:
Gerard Tobin, Peter Nygren, Elin Lindhagen, Christer Sundström, Anna Laurell, Anna Åleskog, Ulf Thunberg, Kenneth Nilsson, Martin Höglund, Göran Roos, Rolf Larsson, Richard Rosenquist
Publikováno v:
European Journal of Haematology. 73:407-411
Objective: B-cell chronic lymphocytic leukaemia (B-CLL) can be divided into two clinical entities based on the immunoglobulin variable heavy chain (V H ) gene mutation status, as cases with unmutated V H genes display a more aggressive disease with s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6af81d1957478d6002289d585573b58f
https://doi.org/10.1111/j.1600-0609.2004.00334.x
https://doi.org/10.1111/j.1600-0609.2004.00334.x
Publikováno v:
Drug Development Research. 61:218-226
When a candidate drug enters clinical trials, decisions regarding dosing are mainly based on animal data. Occasionally, toxicity problems are faced in the clinic because of unexpected species differences in pharmacokinetics or pharmacodynamics betwee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7d69de06ac0ed833ad9289441dd5ecc6
https://doi.org/10.1002/ddr.10353
https://doi.org/10.1002/ddr.10353
Autor:
Martin Höglund, Elin Lindhagen, Monica Hermansson, Anna Åleskog, Rolf Larsson, Jenny Pettersson
Publikováno v:
Leukemia Research. 29:1079-1081
The correlation between drug sensitivity in vitro and the mutation status of the FLT3 receptor gene was evaluated in tumour cells from 17 previously untreated AML patients. Tumour cells with internal tandem duplication (ITD) in the FLT3 receptor gene
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67a05f868fa1e21370cf7f5f44612aa9
https://doi.org/10.1016/j.leukres.2005.02.017
https://doi.org/10.1016/j.leukres.2005.02.017
Autor:
Maria, Norberg, Elin, Lindhagen, Meena, Kanduri, Linda, Rickardson, Christer, Sundström, Kostas, Stamatopoulos, Richard, Rosenquist, Anna, Åleskog
Publikováno v:
Anticancer research. 32(8)
For chronic lymphocytic leukemia (CLL) patients with poor-prognostic genomic aberrations the therapeutic options are limited. We used the Spectrum Collection library to identify compounds with anti-leukemia activity in high-risk CLL.We identified sub
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3c125a50b239f2d4d05ab7752efbb84d
https://pubmed.ncbi.nlm.nih.gov/22843883
https://pubmed.ncbi.nlm.nih.gov/22843883
Autor:
Elin Lindhagen, Caroline Haglund, Anna Åleskog, Malin Wickström, Peter Nygren, Martin Höglund, Joachim Gullbo, Rolf Larsson
Publikováno v:
Cancer chemotherapy and pharmacology. 69(3)
The aim of this study was to evaluate a phenotypic cell panel with tumor cells from various patients and normal cells for preclinical profiles of antitumor efficacy and toxicity of anticancer drugs.The antitumor activity of fourteen anticancer drugs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c380ee733599f107272980b50745740e
https://pubmed.ncbi.nlm.nih.gov/21984220
https://pubmed.ncbi.nlm.nih.gov/21984220